两项手术术式被紧急叫停！此前已在多家大医院开展

Core Viewpoint - The article discusses the recent bans by the National Health Commission on two surgical procedures for treating Alzheimer's disease and type 2 diabetes, highlighting the rise of unproven medical technologies and the need for regulatory oversight [1][2]. Group 1: Surgical Procedures Banned - The National Health Commission has prohibited the clinical application of "cervical deep lymphatic vessel/lymph node-venous anastomosis" for Alzheimer's treatment and "ileal-jejunal anastomosis" for type 2 diabetes treatment due to lack of authoritative guidelines and high-level medical evidence [1][2]. - Both surgical techniques have been applied beyond their intended indications in some hospitals, leading to concerns about patient safety and the potential for serious complications [2][10]. Group 2: Clinical Evidence and Guidelines - The latest "Chinese Diabetes Prevention and Treatment Guidelines" (2024 edition) does not include ileal-jejunal anastomosis as a recommended metabolic surgery, despite its promotion in some hospitals [5][6]. - Research on the use of ileal-jejunal anastomosis for type 2 diabetes is limited, with few studies published in low-impact journals [6]. Group 3: Emerging Technologies - The "cervical deep lymphatic vessel-venous anastomosis" (LVA) is a novel technique being explored for Alzheimer's treatment, with ongoing clinical research in several hospitals across China [12][19]. - LVA has shown potential in treating neurodegenerative diseases, but its mechanisms and effectiveness remain unproven, necessitating further clinical trials and standardized protocols [15][19]. Group 4: Regulatory Actions - The National Health Commission has emphasized the need for strict regulatory oversight of clinical trials and the application of new surgical techniques, urging local health authorities to monitor and halt unauthorized practices [17][18].